CVL-751-PD-003: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa-Treated Adults

Grants and Contracts Details

StatusFinished
Effective start/end date8/3/2010/12/23

Funding

  • Syneos Health LLC: $29,569.00